Biotech

Celmatix and Global Collaborators Release Findings from Largest Genetic Study to Date on Endometriosis

Celmatix, a leading biotech company specializing in ovarian biology for women’s health, has released the findings from a long-term research collaboration with the University of Oxford and 24 other institutions to decode the genetic underpinnings of endometriosis. This condition affects approximately 1 in 10 women worldwide (190 million globally) and has enormous implications for the quality of life. The severe inflammatory condition…

Biotech Startup theblood Raises Close to €1M in Pre-Seed Funding for Its Menstrual Blood Testing Solution and Biomarker Research

Berlin-based startup theblood has raised close to €1M in pre-seed funding to advance research on menstrual blood analysis and biomarkers as well as the development of a non-invasive blood at-home test that helps menstruators monitor their health. The round was led by RoX Health with participation from Leanox VC and several business angels including HealthHero and Fernarzt Founder Felix Kaiser, Prof. Dr.…

Cedars-Sinai Study Could Help Pave the Way to Early Diagnosis and Treatment for Pregnancy-Related Mood Disorders

According to the Centers for Disease Control and Prevention, around 1 in 8 women experience significant symptoms of perinatal mood and anxiety disorders that can negatively impact their overall health, daily activities, and family life. Cedars-Sinai investigators have now discovered that women who developed mood and anxiety disorders related to pregnancy and childbirth had altered proteins circulating in their bloodstream during the…

Consumer Biotech Company Tally Health Launches a New Platform Aimed at Extending Longevity

David Sinclair, a genetics professor at Harvard University, has spent his career researching the aging process and how it can be reversed using epigenetic modifications. Sinclair’s lab recently published a model that explains how aging works and how it can be reversed. By experimenting with mice, Sinclair’s team identified the epigenome as the primary driver of aging, and they successfully rebooted old…

Gameto Licenses Wyss Institute’s Technology for Growing Human Ovaries from Harvard University

For decades, scientists have been studying the human reproductive system in order to better understand it and develop treatments for various reproductive conditions. Despite this, the ovaries – the organs responsible for producing and releasing eggs in women – have remained surprisingly understudied. Researchers have long sought to create in vitro models of human ovaries, which would allow for more in-depth study…

Biotech Company HBM Alpha Therapeutics Adds Seed Funding to Advance Next-Gen Therapies for PCOS and Congenital Adrenal Hyperplasia

Biotech company HBM Alpha Therapeutics has raised a seed round to advance its novel antibody therapies to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), with the lead candidate currently in IND-enabling stage. HBMAT was founded on the expertise of Harbour BioMed’s antibody discovery and development capabilities, and expertise in the molecular pathogenesis and treatment of endocrine disorders of HBMAT’s…

New Data Suggests Daré Bioscience’s Intravaginal Ring Can Help Manage Vasomotor and Vaginal Menopause Symptoms

Menopause is defined as the final menstrual period and is typically confirmed after a woman has missed her period for 12 consecutive months. Most women experience menopause between ages 40 and 58. An estimated 45 million women in the U.S. are approaching or in menopause, which results in a decrease in estrogen and other hormones. Hot flashes, vaginal dryness and loss of bone density are…

Male Contraception Initiative Invests $800K in Eppin Pharma to Support Clinical Trials for a Non-Hormonal Contraceptive

Male Contraceptive Initiative (MCI), a non-profit, has partnered with the pharmaceutical company Eppin Pharma to provide a Program Related Investment (PRI) of up to $800K to support clinical trial activities for the company’s novel short-term, non-hormonal oral male contraceptive pill. Eppin Pharma’s lead male contraceptive candidate is a small organic compound that binds to EPPIN, a protein on the surface of human…